Our company history

1978 saw the founding of Institut Virion\Serion GmbH in the city of Wurzburg in southern Germany.

From the outset the company has specialized in the manufacture of in vitro diagnostic products for the infectious disease serology and has, due to continual growth, twice expanded into new premises since then.

1978
Company foundation in Wurzburg
Foundation of the Institut Virion\Serion GmbH with the product line SERION CFT reagents in Wurzburg (Germany).
1981
Extension of the product portfolio
Introduction of our second product line SERION ELISA classic for detection of pathogen-specific antibodies.
1986
Foundation SERION Immundiagnostica GmbH
Foundation of SERION Immundiagnostica GmbH for handling our foreign trade in our in vitro diagnostics.
2000
CE-Certification
CE-Certification of research and development, production and sales of our in vitro diagnostics in order to secure our high quality standards.
2003
Base in China
Set up of a foreign representation in Peking. At the same time Institut Virion/Serion registered the complete ToRCH panel of the product line SERION ELISA classic as the first company worldwide to do so in China.
2004
Extension
Relocation of Institut Virion\Serion GmbH to the Science-park in the eastern part of the city of Wurzburg, necessary due to continuously increasing number of employees.
2007
Market launch Immunomat
Market launch of the Immunomat for an effective automated processing and analysis of SERION ELISA Immunoassays.
2008
Development Multianalyt
Development of a particle-based product line, SERION Mulianalyt, for the simultaneous quantification of multiple parameters in a small volume.
2011
Center of Excellence
Construction of the new building Center of Excellence mainly for the Research and Development department.
2013
Launch of SERION Immunologics
Launch of the Product division SERION Immunologics for the distribution of high quality raw materials e.g. bulk Antigens, Disease State Sera and Monoclonal Antibodies and different customized solutions.
2015
TOP JOB Certificate
Awarded with the TOP JOB Certificate. 2015 Institut Virion\Serion counted among the best employers in the category medium-sized German business.
2016
Foundation Virion\Serion Biotechnology (Shenzhen) Co., Ltd.
Foundation of Virion\Serion Biotechnology (Shenzhen) Co., Ltd. to intensify our activities on the Chinese market.
2018
Launch SERION Diagnostics
Launch of the Product division SERION Diagnostics to focus deeper on the in vitro diagnostics of the Institut Virion\Serion GmbH.
2018
Forty years of Virion\Serion
Our company anniversary is celebrated with the launch of a new Corporate Design and a brand new website.
2020
TOP JOB Certificate
Institut Virion\Serion GmbH has been awarded the TOP JOB certificate for the second time.
2020
Antibody tests for SARS-CoV-2
Shortly after the start of the COVID-19 pandemic, Virion\Serion launches the fully automatable SERION ELISA agile SARS-CoV-2 IgA, IgG and IgM immunoassays. In an independent comparison with seven competitor assays, the IgG test achieves excellent results.
2021
Research project SeptoSurvive
The German Federal Ministry of Education and Research (BMBF) funds the joint project SeptoSurvive, which aims to cut the time needed for an antibiotic resistance profile in sepsis from 24 hours to 4–6 hours. Virion\Serion develops microparticle-based components for isolating pathogens from patient samples.
© Fraunhofer ILT, Aachen / Volker Lannert
2023
45 years of Virion\Serion
Institut Virion\Serion GmbH celebrates 45 years of experience in the development and manufacture of in vitro diagnostics.
2024
IVDR certification class C
Our class C products are certified under the new EU In Vitro Diagnostic Regulation (IVDR, Regulation (EU) 2017/746).
2025
IVDR certification class B
With the certificate for our class B products, all SERION ELISA products of classes B and C are now certified under the new regulation.
2026
Change in management
After many years at the helm, Dr. Judith Stuermer, who built and shaped the company together with its founder, leaves Virion\Serion. On 1 May, Maik Lander takes over as sole Managing Director of Institut Virion\Serion GmbH.
2026
SERION autoimmune
SERION Immunologics expands its portfolio with recombinant autoimmune antigens, produced under ISO 13485 for the development of autoantibody assays.